Dr. Bauml Discusses a New Electronic Platform for Clinical Trial Enrollment in Lung Cancer
Joshua M. Bauml, MD, assistant professor, University of Pennsylvania, discusses the significant impacts of a new electronic platform.
Joshua M. Bauml, MD, assistant professor, University of Pennsylvania, discusses the significant impacts of a new electronic platform.
Bauml hopes the new platform will enhance clinical trial enrollment in lung cancer. To achieve this, first the feasibility of the approach had to be established. Bauml and his team considered whether the platform was burdensome or overwhelming to patients as well. However, he found that patients tend to like this type of technology.
The rate of clinical trial enrollment is 5% nationally and 10%-15% in an academic center, says Bauml. He adds that he and his team were able to achieve 40% clinical trial enrollment, which included those who were appropriate for therapy change.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
